Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020
August 04 2020 - 6:30AM
Heidelberg, Germany, August 4,
2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer, announced today that it will
release second quarter 2020 results on Tuesday, August 11, 2020 and
host a conference call at 8:30 a.m. EDT to discuss financial
results and corporate developments.
The conference call will be available via phone and webcast. To
access the first quarter results call, please dial +1-646-741-3167
for U.S. callers, or +44 (0) 2071 928338 for international callers,
and reference conference ID 8855368 approximately 15 minutes prior
to the call.
To access the live audio webcast of the conference call please
visit the “Investors” section of company’s website at
https://www.affimed.com/investors/webcasts_cp/. A replay of the
call will be archived on the Affimed website for 30 days after the
call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The company is developing single and combination
therapies to treat hematologic and solid tumors. The company is
currently enrolling patients into a registration-directed study of
AFM13 for CD30-positive relapsed/refractory peripheral T cell
lymphoma and into a Phase 1/2a dose escalation/expansion study of
AFM24 for the treatment of advanced EGFR-expressing solid tumors.
For more information, please visit www.affimed.com.
Investor & Media Contact:
Alex FudukidisHead of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel: (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024